Hepatitis C, stigma and cure

被引:72
作者
Marinho, Rui Tato [1 ]
Barreira, David Pires [1 ]
机构
[1] Hosp Santa Maria, Dept Gastroenterol & Hepatol, Med Sch Lisbon, P-1649035 Lisbon, Portugal
关键词
Hepatitis C; Chronic; Therapy; Hepatocellular carcinoma; Hepatic cirrhosis; Interferon-alpha; Ribavirin; Social stigma; Depression; QUALITY-OF-LIFE; SUSTAINED VIROLOGICAL RESPONSE; NATURAL-HISTORY; INTERFERON-ALPHA; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL THERAPY; SPLENIC LYMPHOMA; VIRUS-INFECTION; NON-A; DEPRESSION;
D O I
10.3748/wjg.v19.i40.6703
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The infection with hepatitis C virus (HCV) is one of the most important global chronic viral infections worldwide. It is estimated to affect around 3% of the world population, about 170-200 million people. Great part of the infections are asymptomatic, the patient can be a chronic carrier for decades without knowing it. The most severe consequences of the chronic infection are liver cirrhosis and hepatocellular carcinoma, which appears in 20%-40% of the patients, leading to hepatic failure and death. The HCV was discovered 25 years ago in 1989, is a RNA virus and classified by the World Health Organization as an oncogenic one. Hepatocellular carcinoma is one of the most important cancers, the fifth worldwide in terms of mortality. It has been increasing in the Ocidental world, mainly due to chronic hepatitis C. Hepatitis C is not only a liver disease and a cause of cirrhosis, but also a mental, psychological, familiar, and social disease. The stigma that the infected person sometimes carries is tremendous having multiple consequences. The main cause is lack of adequate information, even in the health professionals setting. But, besides the "drama" of being infected, health professionals, family, society and the infected patients, must be aware of the chance of real cure and total and definitive elimination of the virus. The treatment for hepatitis C has begun in the last 80's with a percentage of cure of 6%. Step by step the efficacy of the therapy for hepatitis C is rapidly increasing and nowadays with the very new medications, the so called Direct Antiviral Agents-DAAs of new generation, is around 80%-90%. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码:6703 / 6709
页数:7
相关论文
共 65 条
  • [31] Johnson ME, 1998, AM J GASTROENTEROL, V93, P785
  • [32] Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study
    Koskinas, J.
    Kilidireas, C.
    Karandreas, N.
    Kountouras, D.
    Savvas, S.
    Hadziyannis, E.
    Archimandritis, A. J.
    [J]. LIVER INTERNATIONAL, 2007, 27 (03) : 414 - 420
  • [33] AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS
    KUO, G
    CHOO, QL
    ALTER, HJ
    GITNICK, GL
    REDEKER, AG
    PURCELL, RH
    MIYAMURA, T
    DIENSTAG, JL
    ALTER, MJ
    STEVENS, CE
    TEGTMEIER, GE
    BONINO, F
    COLOMBO, M
    LEE, WS
    KUO, C
    BERGER, K
    SHUSTER, JR
    OVERBY, LR
    BRADLEY, DW
    HOUGHTON, M
    [J]. SCIENCE, 1989, 244 (4902) : 362 - 364
  • [34] A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
    Lawitz, Eric
    Poordad, Fred
    Kowdley, Kris V.
    Cohen, Daniel E.
    Podsadecki, Thomas
    Siggelkow, Sara
    Larsen, Lois
    Menon, Rajeev
    Koev, Gennadiy
    Tripathi, Rakesh
    Pilot-Matias, Tami
    Bernstein, Barry
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (01) : 18 - 23
  • [35] Lawitz E, 2013, NEW ENGL J MED, V369, P678, DOI [10.1056/NEJMoa1214853, 10.1056/NEJMc1307641]
  • [36] New Protease Inhibitors for the Treatment of Chronic Hepatitis C A Cost-Effectiveness Analysis
    Liu, Shan
    Cipriano, Lauren E.
    Holodniy, Mark
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (04) : 279 - U68
  • [37] Longo S, 2010, J Ultrasound, V13, P164, DOI 10.1016/j.jus.2010.10.013
  • [38] The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    Loomba, R.
    Rivera, M. M.
    McBurney, R.
    Park, Y.
    Haynes-Williams, V.
    Rehermann, B.
    Alter, H. J.
    Herrine, S. K.
    Liang, T. J.
    Hoofnagle, J. H.
    Heller, T.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (05) : 559 - 565
  • [39] Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
    Marcellin, P
    Boyer, N
    Gervais, A
    Martinot, M
    Pouteau, M
    Castelnau, C
    Kilani, A
    Areias, J
    Auperin, A
    Benhamou, JP
    Degott, C
    Erlinger, S
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 875 - +
  • [40] Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus
    Marinho, RT
    Pinto, RM
    Santos, ML
    de Moura, MC
    [J]. LIVER INTERNATIONAL, 2004, 24 (05) : 413 - 418